Demystifying Synthetic Biology III: The 21st Century Technologies Advancing Synthetic Biology

Synthetic biology is often touted as a software-driven and automation-empowered approach to biological research. Buzzwords like artificial intelligence and robotics are commonly used alongside the phrase synthetic biology, leading…
Introducing CPO Heidi Pucel

Growth and change can be challenging within dynamic, evolving startups, but it’s easier to navigate when you are tuned in to how people experience the world. Heidi Pucel, Antheia’s new Chief People Officer, knows a thing or two about this…
Antheia Senior Scientist Involved in Cancer Research Discovery

Senior Scientist Chunshun Li received accolades for his contribution to a recent University of Hawaii Cancer Center discovery. In support of lead researcher Shugeng Cao, associate member of the Cancer Biology Program…
Demystifying Synthetic Biology II: Molecular Biology Advancements Enabling Synthetic Biology

Synthetic biology seems like a brand-new, precision scientific field – just bursting with potential – but is it really all that new? Biology is often seen as the unpredictable cousin of the math-based sciences chemistry and physics…
Syn Bio Companies Put the Earth into Focus

While some synthetic biology companies are using biology to improve our food, clothes, and medicine, others are turning their attention to helping the Earth.
Demystifying Synthetic Biology: Building with the power of biology

Technology today is defined by superlatives: we have the fastest cars, the best medicine, and the most advanced communication tools ever known. Yet despite humanity’s technological progress…
Antheia Appoints Heidi Pucel as Chief People Officer
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced the appointment of Heidi Pucel as its Chief People Officer. Pucel joins the company as it prepares to significantly increase…
Seven Biopharma Trends to Watch in 2022

Synthetic biology attracted $8.9 billion in venture funding during the first half of 2021, according to synbio stakeholder group SynBioBeta, and launched two successful initial public offerings: Zymergen’s $529.6 million traditional IPO and Ginkgo Bioworks…
Dr. Christina Smolke of Antheia On The 5 Leadership Lessons She Learned From Her Experience

As a part of my series about “Lessons From Inspirational Women in STEM and Tech”, I had the pleasure of interviewing Christina Smolke…
Introducing Zack McGahey, Antheia’s COO

Antheia is at a critical point in scaling our production technology. Just as we bring together exceptional science and technologies to unleash the power of plants to inspire the next generation of medicines…